Cargando…
Exploring natural killer cell immunology as a therapeutic strategy in lung cancer
Cytotoxic immune cells are key in the control of tumor development and progression. Natural killer (NK) cells are the cytotoxic arm of the innate immune system with the capability to kill tumor cells and surveil tumor cell dissemination. As such, the interest in harnessing NK cells in tumor control...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264324/ https://www.ncbi.nlm.nih.gov/pubmed/34295678 http://dx.doi.org/10.21037/tlcr-20-765 |
_version_ | 1783719529482813440 |
---|---|
author | Hess, Jonas B. Sutherland, Kate D. Best, Sarah A. |
author_facet | Hess, Jonas B. Sutherland, Kate D. Best, Sarah A. |
author_sort | Hess, Jonas B. |
collection | PubMed |
description | Cytotoxic immune cells are key in the control of tumor development and progression. Natural killer (NK) cells are the cytotoxic arm of the innate immune system with the capability to kill tumor cells and surveil tumor cell dissemination. As such, the interest in harnessing NK cells in tumor control is increasing in many solid tumor types, including lung cancer. Here, we review the pre-clinical models used to unveil the role of NK cells in immunosurveillance of solid tumors and highlight measures to enhance NK cell activity. Importantly, the development of NK immunotherapy is rapidly evolving. Enhancing the NK cell response can be achieved using two broad modalities: enhancing endogenous NK cell activity, or performing adoptive transfer of pre-activated NK cells to patients. Numerous clinical trials are evaluating the efficacy of NK cell immunotherapy in isolation or in combination with standard treatments, with encouraging initial results. Pre-clinical studies and early phase clinical trials suggest that patients with solid tumors, including lung cancer, have the potential to benefit from recent developments in NK cell immunotherapy. |
format | Online Article Text |
id | pubmed-8264324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-82643242021-07-21 Exploring natural killer cell immunology as a therapeutic strategy in lung cancer Hess, Jonas B. Sutherland, Kate D. Best, Sarah A. Transl Lung Cancer Res Review Article on Lung Cancer and The Immune System Cytotoxic immune cells are key in the control of tumor development and progression. Natural killer (NK) cells are the cytotoxic arm of the innate immune system with the capability to kill tumor cells and surveil tumor cell dissemination. As such, the interest in harnessing NK cells in tumor control is increasing in many solid tumor types, including lung cancer. Here, we review the pre-clinical models used to unveil the role of NK cells in immunosurveillance of solid tumors and highlight measures to enhance NK cell activity. Importantly, the development of NK immunotherapy is rapidly evolving. Enhancing the NK cell response can be achieved using two broad modalities: enhancing endogenous NK cell activity, or performing adoptive transfer of pre-activated NK cells to patients. Numerous clinical trials are evaluating the efficacy of NK cell immunotherapy in isolation or in combination with standard treatments, with encouraging initial results. Pre-clinical studies and early phase clinical trials suggest that patients with solid tumors, including lung cancer, have the potential to benefit from recent developments in NK cell immunotherapy. AME Publishing Company 2021-06 /pmc/articles/PMC8264324/ /pubmed/34295678 http://dx.doi.org/10.21037/tlcr-20-765 Text en 2021 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Article on Lung Cancer and The Immune System Hess, Jonas B. Sutherland, Kate D. Best, Sarah A. Exploring natural killer cell immunology as a therapeutic strategy in lung cancer |
title | Exploring natural killer cell immunology as a therapeutic strategy in lung cancer |
title_full | Exploring natural killer cell immunology as a therapeutic strategy in lung cancer |
title_fullStr | Exploring natural killer cell immunology as a therapeutic strategy in lung cancer |
title_full_unstemmed | Exploring natural killer cell immunology as a therapeutic strategy in lung cancer |
title_short | Exploring natural killer cell immunology as a therapeutic strategy in lung cancer |
title_sort | exploring natural killer cell immunology as a therapeutic strategy in lung cancer |
topic | Review Article on Lung Cancer and The Immune System |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264324/ https://www.ncbi.nlm.nih.gov/pubmed/34295678 http://dx.doi.org/10.21037/tlcr-20-765 |
work_keys_str_mv | AT hessjonasb exploringnaturalkillercellimmunologyasatherapeuticstrategyinlungcancer AT sutherlandkated exploringnaturalkillercellimmunologyasatherapeuticstrategyinlungcancer AT bestsaraha exploringnaturalkillercellimmunologyasatherapeuticstrategyinlungcancer |